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Abstract 
 
Coronary heart disease (CHD) is one of the major causes of disability in adults as well as one of 
the main causes of death in the developed countries. Although significant progress has been made in the 
diagnosis and treatment of CHD, further investigation is still needed. The objective of this study was to 
develop the assessment of heart event-risk factors targeting in the reduction of CHD events using 
Association Rule Mining. The risk factors investigated were: 1) before the event: a) non modifiable—age, 
sex, and family history for premature CHD, b) modifiable—smoking before the event, history of 
hypertension, and history of diabetes; and 2) after the event: modifiable—smoking after the event, 
systolic blood pressure, diastolic blood pressure, total cholesterol, high density lipoprotein, low-density 
lipoprotein, triglycerides, and glucose. The events investigated were: myocardial infarction (MI), 
percutaneous coronary intervention (PCI), and coronary artery bypass graft surgery (CABG).Data-mining 
analysis was carried out using the Association Rule Mining for the afore mentioned three events using 
five different splitting criteria for larger datasets. The most important risk factors, as extracted from the 
classification rules analysis were: 1) for MI, age, smoking, and history of hypertension; 2) for PCI, family 
history, history of hypertension, and history of diabetes; and 3) for CABG, age, history of hypertension, 
and smoking. It is anticipated that data mining could help in the identification of high and low risk 
subgroups of subjects, a decisive factor for the selection of therapy, i.e., medical or surgical. 
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1. INTRODUCTION 
Coronary heart disease (CHD) is the single most common cause of death in Europe, responsible 
for nearly two million deaths a year. Advances in the field of medicine over the past few decades enabled 
the identification of risk factors that may contribute toward the development of CHD. However, this 
knowledge has not yet helped in the significant reduction of CHD incidence. There are several factors that 
contribute to the development of a coronary heart event. These risk factors may be classified into two 
categories, not modifiable and modifiable. The first category includes factors that cannot be altered by 
intervention such as age, gender, operations, family history, and genetic attributes. Modifiable risk factors 
are those for which either treatment is available or in which alternations in behavior can reduce the 
proportion of the population exposed. Established, modifiable risk factors for CHD currently include 
smoking, hypertension, diabetes, cholesterol, high-density lipoprotein, low-density lipoprotein, 
triglyceride 
Data-mining analysis was carried out using the association rule mining using five different 
splitting criteria for extracting rules based on the aforementioned risk factors. Preliminary results of this 
study were previously published. In order to improve the patient safety and avoid the underreporting bias, 
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this paper aims at automatically discovering CHDs that occurred in inpatients. This will be done by 
identifying situations at risk of CHD by data mining of routinely collected data of past hospitalizations. In 
those data, the CHDs are not explicitly flagged as no preliminary review is performed. Outpatients’ CHDs 
leading to hospitalization will not be studied. 
A list of outcomes will first be defined, and the link between those outcomes and prior drug 
administration or discontinuations will be studied by means of association rule mining techniques applied 
on a training set. Rules will be obtained, in which an outcome is explained by a set of drugs in 
combination with a clinical background, in the form of ADE detection rules (e.g., drug_A & 
background_B → outcome_C). Then those rules will be applied onto past hospital stays of an evaluation 
set to get contextualized statistics such as the confidence (e.g., probability of outcome_C when drug_A 
and background_B are present). Regarding data mining techniques, two issues have to be solved: 
 
1) the temporal constraints have to be taken into account; and  
2) we have to use supervised rule-induction methods, although the ADEs are not explicitly  flagged 
in the routinely collected data, which are usually required in the classical rule induction method 
 
 
TABLE 1: Description of the Hospitals and Stays Used 
 
 
Hospital No of Age Men Duration 
 stays in yrs proportion in days 
     
French#1 50072 52.8 29.2% 5.48 
     
French#2 1367 71.4 42.1% 11.4 
     
Danish#1 26245 45.4 51.6% 10.7 
     
Bulgarian 6880 49.4 26.4% 6.96 
     
 
  
2. MATERIALS AND METHODS 
Data Collection, Cleaning, and Coding Data from 1500 consecutive CHD subjects were collected 
between the years 2003–2006 and 2009 (300 subjects each year) according to a prespecified protocol, 
under the supervision of the participating cardiologist (Dr.J. Moutiris, second author of this paper) at the 
Department of Cardiology, a the Paphos General Hospital in Cyprus. Subjects had at least one of the 
following criteria on enrollment, history of MI, or percutaneous coronary intervention (PCI), or coronary 
artery bypass graft surgery (CABG). Data for each subject were collected as given in Table 1: 1) risk 
factors before the event, a) non modifiable— age, sex, and family history (FH); 2) modifiable— smoking 
before the event (SMBEF), history of hypertension (HxHTN), and history of diabetes (HxDM); and 2) 
risk factors after the event, modifiable—smoking after the event (SMAFT), systolic blood pressure (SBP) 
in mmHg, diastolic blood pressure (DBP) in mmHg, total cholesterol (TC) in mg/dL, high-density 
lipoprotein (HDL) in mg/dL, low-density lipoprotein (LDL) in mg/dL, triglycerides (TG) in mg/dL, and 
glucose (GLU) in mg/dL. 
To clean the data, the fields were identified, duplications were extracted, missing values were 
filled, and the data were coded as given in Table 2. After data cleaning, the number of cases was reduced 
as given in Table 3, mainly due to unavailability of biochemical results. 
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TABLE 2: Coding of Risk Factors 
 
Risk factors before the event : non modifiable 
 
Risk Code1 Code 2 Code3 Code4 
factor     
AGE 1:34-5  2:51-6 3:61-7 
SEX M:male F:female   
     
FH Y:yes N:no   
 
Risk factors before the event: modifiable 
  
SMBEF Y:yes N:no 
HxHTN Y:yes N:no 
HxDM Y:yes N:no 
 
 
Table 3: No. of Cases Per Set of Rules/Models Investigated 
 
 Model MI PCI CABG 
Event Yes 378/75/75 72/36/36 86/43/43 
 
    
No 150/75/75 274/36/36 307/43/43 
 
 
2.1 Aggregation of the Complex Data of the Stays Into Simple Events General Principles 
The data described in the data repository are characterized by a complex data scheme, very 
numerous classes (about 17 000 codes for ICD10, about 5400 codes for the ATC, etc.) and repeated 
measurements throughout the hospitalization (e.g., laboratory parameters and drug administrations). 
Those characteristics make those data too complex to be mined using statistical methods. The aim of the  
data-to-event aggregation process is to automatically get a simpler representation of data for data mining 
purposes. Aggregation engines are developed in order to transform the available data into information 
described as sets of events. For each kind of data (administrative information, diagnoses, drugs, and 
laboratory results), a specific aggregation engine is developed and fed with a mapping. Each mapping is 
described by means of extensible markup language (XML) files outside the engine. The aggregation 
engines enable to describe the events in terms of binary variables complemented by start and stop dates. 
Those engines are not static and can be adapted with respect to the context. 
 
2.2 Identification of the Outcomes in Relation with CHDs  
As described, a list of outcomes is extracted from the summaries of product characteristics. The 
outcomes are traced in the data essentially by screening the laboratory results and administered drugs; this 
is possible through different ways depending on the category of outcome. For instance, the occurrence of 
a hyperkalemia (laboratory-related outcome) is directly traced using the potassium level in the blood. The 
occurrence of a hemorrhage under vitamin K antagonists (VKA) can be traced through different ways: 1) 
an increase of the international normalized ratio (INR), a laboratory parameter that rises up in case of 
VKA overdose; and 2) the vitamin K administration, an antidote which is prescribed in case of 
hemorrhage under VKA. The structured SPC database describes 228 different kinds of outcomes. 83 
(37%) of those outcomes are traceable in this paper, due to the available data. 
Duplicate entries are then removed; for instance, in the initial list, ―hyperbilirubinemia‖ is also 
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described using two synonyms, ―bilirubinemia higher than twice the normal upper bound‖ and 
―jaundice.‖ As a consequence, those 83 outcomes are traced through 56 different variables. Those 
outcomes correspond to life-threatening CHDs, such as hyperkalemia of hemorrhage hazard. 
Unfortunately, some outcomes cannot be traced in the data. This is the case especially for minor clinical 
incidents such as nausea or gastric pain cannot be traced. Those outcomes could correspond to ICD10 
codes but in most hospitals, such codes are not flagged with a date. 
 
2.3 Expert Validation and Reorganization of the Rules : 
It is mandatory to filter, validate, and organize the rules that are obtained from the data mining: as 
the rules have to be used by physicians, they must provide simple, validated, and unquestionable 
knowledge. Several meetings are organized with external experts (physicians, pharmacologists, 
pharmacists, and statisticians) to filter and reorganize the set of rules. The rules are examined and 
validated against the SPCs and scientific references. During the review, the experts may ask for 
complementary queries on the potential CHD cases. At this step, the experts may manually add a few 
rules that are considered as mandatory although they were not discovered by the data mining process, for 
instance because the conditions of the rules never occur (e.g., absolute contraindication) or because the 
conditions occur but do not lead to any outcome. In every rule, there is a set of conditions; the experts are 
asked to characterize each condition according to one of the following types. 
 
 
1) Segmentation: Conditions are conditions that do not explain why an outcome occurs, but deeply 
change its probability. This kind of condition enables us to reduce over alerting.  
2) Subgroup: Conditions are fixed when, for some medical reasons, it does not make sense to consider 
Rules are stored in a rule repository. A machine evaluation automatically computes various statistics 
(occurrences) of the rules in every medical department the sample before computing the statistics. 
The following subgroups are systematically defined. 
 
 The INR deviations or vitamin K administrations are only explored for VKA-treated 
patients. 
 The increase of activated partial thromboplastin time is only explored for heparin-
treated patients. 
 The hyperkalemia is explored separately for patients suffering from renal 
insufficiency or not. 
3) Basic: Conditions group together all the other conditions. 
 
3. RESULTS AND DISCUSSION 
In this paper, 56 different outcomes enable to trace the potential consequences of CHDs. The 
supervised rule induction generates rules that predict each outcome. The rules are always filtered, 
validated, and tuned by the expert committee. 236 validated rules are obtained. The experts also add some 
rules that appear to be important in the academic knowledge and are not discovered by the data mining 
(e.g., the conditions never occur, or occur but not lead to the outcome). Over the 56 outcomes, we have 
the following. 
 
 Twenty-seven kinds of outcomes are observed and enable to discover CHD detection rules. 
 Ten outcomes are never or too rarely observed in the data, so that no rule is discovered. Data mining 
will be performed on larger datasets to get results. 
 Eighteen outcomes are observed but cannot be explained by the use of drugs in the available dataset: 
the medical background of the patient is a sufficient explanation, so that no rule is discovered. 
 
4. CONCLUSION & FUTURE WORK 
This paper brings innovative and semi automated solutions for CHD detection. The method is 
quite generic and could be applied to other kinds of data as soon as they are available in the EHR, such as 
structured results of electrocardiograms. The results of the method used here bring an important 
Vol. 1, No. 1 (2013) 44-48 
 
48 
 
contribution to CHD knowledge. The rules that are obtained are versatile and can be used either as 
detection rules on past hospital stays, or as prevention rules in a CDSS context. Those rules are already 
loaded in several prototypes that are developed in the frame of the PSIP Project. CDSS is the one 
embedded in a computerized physician order entry, another embedded in an EHR, and a prescription 
simulation tool that is available even without any Hospital information system. 
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